MeSH D020529 - relapsing-remitting multiple sclerosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Glatiramer acetate | Copaxone |  | 1996-12-20 | $590 M | Y2023 |
| Fingolimod | Fingolimod |  | 2020-07-02 |  |  | |
| Teriflunomide | Teriflunomide |  | 2018-09-04 |  |  | |
| Dimethyl fumarate | Dimethyl Teva |  | 2022-12-12 |  |  | |
| Glenmark Pharmaceuticals | Fingolimod | Fingolimod |  | 2020-06-18 |  |  |
| Teriflunomide | Teriflunomide |  | 2018-11-15 |  |  | |
| Mylan | Fingolimod | Fingolimod |  | 2021-01-19 |  |  |
| Fingolimod | Fingolimod Mylan |  | 2021-08-18 |  |  | |
| Glatiramer acetate | Glatiramer |  | 2017-10-03 |  |  | |
| Teriflunomide | Teriflunomide |  | 2020-02-28 |  |  | |
| Teriflunomide | Teriflunomide Mylan |  | 2022-11-09 |  |  | |
| Dimethyl fumarate | Dimethyl Mylan |  | 2022-05-13 |  |  | |
| Johnson & Johnson | Ponesimod | Ponvory | 2024-11-16 | 2021-03-18 |  |  |
| Sandoz | Glatiramer acetate | Glatopa |  | 2015-04-16 |  |  |
| Teriflunomide | Teriflunomide |  | 2019-01-03 |  |  | |
| Natalizumab | Tyruko |  | 2023-09-22 |  |  | |
| Novartis | Fingolimod | Gilenya | 2026-03-29 | 2010-09-21 | $2,283 M | Q2/20-Q2/23 |
| Ofatumumab | Kesimpta |  | 2021-03-26 | $794 M | Q2/21-Q2/23 | |
| Siponimod | Mayzent |  | 2020-01-13 | $282 M | Q2/20-Q2/23 | |
| Sanofi | Teriflunomide | Aubagio | 2026-09-12 | 2012-09-12 |  |  |
| Aurobindo Pharma | Teriflunomide | Teriflunomide |  | 2018-10-26 |  |  |
| Fingolimod | Fingolimod |  | 2024-02-28 |  |  | |
| Dr Reddys Laboratories | Fingolimod | Fingolimod |  | 2021-03-05 |  |  |
| Zydus Therapeutics | Fingolimod | Fingolimod |  | 2020-10-14 |  |  |
| Teriflunomide | Teriflunomide |  | 2018-11-30 |  |  |
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
68%15/22
Phase 2
41%29/70
Phase 3
61%47/77
Approved: 13Overall Success rate: 17%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use